Skip to main content
      RT @Janetbirdope: Common sense to ⬇️#rheumatoidarthritis 6S412 G Burmester summarizes decades of RA research - avoid

      Janet Pope Janetbirdope

      4 years ago
      Common sense to ⬇️#rheumatoidarthritis 6S412 G Burmester summarizes decades of RA research - avoidance strategies =healthy lifestyle. ?asked is sero+RA diff than seronegative? Maybe. other Abs likely exist @RheumNow #ACR21 #ACRBest https://t.co/RT3dHDfdWp
      RT @drdavidliew: After elegantly laying out the sophisticated science at #ACR21, Gerd Burmester finishes with this:

      Wit

      David Liew drdavidliew

      4 years ago
      After elegantly laying out the sophisticated science at #ACR21, Gerd Burmester finishes with this: Without waiting, 11 things we can actually do now to reduce our chance of RA @The_IMJ Ranjeny Thomas and @lynmarch1 et al @RheumNow https://t.co/Be1Jyw9FOo
      I'm wearing my badge, just in case... #RheumPix https://t.co/UvgCinq8Bn

      Dr. John Cush RheumNow

      4 years ago
      I'm wearing my badge, just in case... #RheumPix https://t.co/UvgCinq8Bn
      RT @rheum_cat: Spinal involvement: fine, symmetric syndesmophytes (axSpA) vs bulky, asymmetric syndesmophytes (axPsA)

      #

      Rheum Cat rheum_cat

      4 years ago
      Spinal involvement: fine, symmetric syndesmophytes (axSpA) vs bulky, asymmetric syndesmophytes (axPsA) #ACR21 https://t.co/7leGTjm4fb
      RT @RichardPAConway: @AUGarren @DavidLeverenz demonstrate significant gaps in DMARD lab safety monitoring in telehealth

      Richard Conway RichardPAConway

      4 years ago
      @AUGarren @DavidLeverenz demonstrate significant gaps in DMARD lab safety monitoring in telehealth setting. Small improvement over time but still <50% 😱 Abstr#0146 #ACR21 @RheumNow https://t.co/FDp7ZwzfO5
      RT @doctorRBC: Deucravacitinib (TYK2 inhibitor) for PsA tx showed biomarker changes consistent with clinical improvement

      Robert B Chao, MD doctorRBC

      4 years ago
      Deucravacitinib (TYK2 inhibitor) for PsA tx showed biomarker changes consistent with clinical improvement ⬇️IL-23, IL-17 and IFN-1 pathways vs. pbo ⬇️MMP3 (associated with joint damage), C4M Abs#490 #ACR21 @RheumNow https://t.co/mA1aHmtE5I https://t.co/BoAPKiMW9x
      RT @SMerjanah: Skin Findings in Patients of Color with Rheumatic Disease #ACR21.
      Don't miss lupus panniculitis. https:/

      Sali Merjanah SMerjanah

      4 years ago
      Skin Findings in Patients of Color with Rheumatic Disease #ACR21. Don't miss lupus panniculitis. https://t.co/kM6XbFtNoW
      RT @doctorRBC: Brepocitinib (TYK2/JAK1 inhibitor) phase 2b study for PsA treatment
      ⬆️ACR20, 50, 70 response vs. pbo

      Robert B Chao, MD doctorRBC

      4 years ago
      Brepocitinib (TYK2/JAK1 inhibitor) phase 2b study for PsA treatment ⬆️ACR20, 50, 70 response vs. pbo ⬆️secondary outcomes vs. pbo ⬆️serious AE vs. pbo, ⬆️zoster ⭐️no MACE/VTE/death reported Abs#488 #ACR21 @RheumNow https://t.co/KdAHQGjTMZ https://t.co/ugk3rkxX9t
      RT @Janetbirdope: OK am trying to learn about VEXAS ⬇️hearing, periorbital Edelman, chondritis, VTE, pulmonary infil

      Janet Pope Janetbirdope

      4 years ago
      OK am trying to learn about VEXAS ⬇️hearing, periorbital Edelman, chondritis, VTE, pulmonary infiltrates, Sweets, Arthritis. Genetic adult auto inflammatory syndrome ⬆️Men Rx steroids, then IL6i, etc. IL1i has ⬆️skin reactions 6S410 #ACR21 #gamechanger @RheumNow #ClinicalPearl https://t.co/OYRi1yAal5
      RT @_Castillo_Pedro: Too many great points in this presentation! Making sense of the IL-23 inhibitor failure in axSpA st

      Pedro Castillo _Castillo_Pedro

      4 years ago
      Too many great points in this presentation! Making sense of the IL-23 inhibitor failure in axSpA studies. From Dr. Atul Deodhar's presentation at #ACR21 6S403 session @RheumNow https://t.co/Iv0LCNob5J
      RT @AkhilSoodMD: Abst 0482
      Baker and colleagues showed that in patients with Type 2 DM, metformin use is associated wit

      Akhil Sood MD AkhilSoodMD

      4 years ago
      Abst 0482 Baker and colleagues showed that in patients with Type 2 DM, metformin use is associated with significantly lower risk of developing #OA and time to joint replacement #ACR21 @RheumNow https://t.co/a00g3HMrM0
      RT @RichardPAConway: 🚨 DESIRES study. DB RCT in systemic sclerosis. Significant benefit of Rituximab in Rodnan skin s

      Richard Conway RichardPAConway

      4 years ago
      🚨 DESIRES study. DB RCT in systemic sclerosis. Significant benefit of Rituximab in Rodnan skin score and FVC! Abstr#496 #ACR21 @RheumNow #ACRBest https://t.co/Ta6Cq8XZie
      RT @Janetbirdope: Cool talk by P Grayson - how to design ANCA vasculitis RCTs with biomarkers, umbrella/basket RCT desig

      Janet Pope Janetbirdope

      4 years ago
      Cool talk by P Grayson - how to design ANCA vasculitis RCTs with biomarkers, umbrella/basket RCT designs to treat pts MORE likely to respond. Also for an individual, following ANCA is not that helpful for altering Rx Take a look at this session GS401 #ACR21 #ACRBest @RheumNow https://t.co/nrapO9i4gw
      RT @AkhilSoodMD: Abst 0478
      Binvignat et al performed hierarchical clustering analysis based on cardinal symptoms in hand

      Akhil Sood MD AkhilSoodMD

      4 years ago
      Abst 0478 Binvignat et al performed hierarchical clustering analysis based on cardinal symptoms in hand OA - Identified 5 Phenotypes - Symptoms correlated with metabolic syndrome, joint destruction & physical and psychological burden #ACR21 @RheumNow https://t.co/O9hweqNIS8
      ×